RAFAEL HOLDINGS, INC. Debt and Equity Securities, Unrealized Gain (Loss)
RAFAEL HOLDINGS, INC. (RFL) reported Debt and Equity Securities, Unrealized Gain (Loss) of $2.10 million for the 3-month period ending 2023-10-31, per its 10-Q filed 2023-12-14.
Discontinued › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss · last filed 2023-12-14
- RAFAEL HOLDINGS, INC. debt and equity securities, unrealized gain (loss) for the quarter ending 2023-10-31 was $2.10M.
| Period end | Debt and Equity Securities, Unrealized Gain (Loss) 3 month |
|---|---|
| 2023-10-31 | $2.10M 10-Q · filed 2023-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |